Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

United States

The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania

Spain

Hospital Universitario Vall d'Hebron - Oncología Médica, Barcelona